B+
Bull case
25%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
URGN
UroGenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The supported bull case is that UroGen now has two meaningful value drivers at once: ZUSDURI reimbursement friction improved after the January 1, 2026 J-code effective date, and UGN-103 has a defined regulatory path after the UTOPIA data. If launch metrics keep compounding and the NDA timeline holds, the stock has room to move toward a more development-plus-commercial multiple.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cash, cash equivalents, and marketable securities were $120.5 million at December 31, 2025, while net loss was $153.5 million for 2025, keeping funding and cash-burn monitoring important.
Momentum
30
Value
41
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $33.00 · Bear $16.00Analysis 2026-05-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $60.00
Why
Momentum30 · Δ7d -38.5
Value41 · Δ7d -0.1
Sentiment28 · Δ7d +0.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Cash, cash equivalents, and marketable securities were $120.5 million at December 31, 2025, while net loss was $153.5 million for 2025, keeping funding and cash-burn monitoring important.
- • Full-year 2026 operating expense guidance of $240 million to $250 million is high relative to current scale, so commercial underperformance could pressure sentiment quickly.
- • The supported bear case is that the story still depends on proving early ZUSDURI utilization can scale while operating expenses remain elevated and pipeline milestones remain forward-looking.
Catalyst clock
2026-08-01
ZUSDURI post-J-code launch conversion is the near-term proof point
Lead driver: Value · See fundamentals
Momentum
30
8% active weight
Current posture
7d trendSoftening
Δ7d
-38.5
Δ21d
-59.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
28
45% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+11.6
Why this grade
Composite grade F. Momentum 30.3 / Value 40.6 / Sentiment 28.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-01. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.69B
Beta
1.35
Shares Out
48.88M
P/E (TTM) · Derived
-10.8
P/S (TTM)
10.73
P/FCF (TTM) · Derived
-9.93
Rev YoY
+199.2%
EPS YoY
-72.8%
Gross Margin
+90.8%
Op Margin
-35.3%
Net Debt
$8.28M
Current Ratio
3.80
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data